Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

Anja Kafka, Davor Tomas, Mirna Lechpammer, Tea Gabud, Leo Pažanin, Nives Pećina-Šlaus

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The expression patterns of critical molecular components of Wnt signaling, sFRP3 and DVL3, were investigated in glioblastoma, the most aggressive form of primary brain tumors, with the aim to offer potential biomarkers. The protein expression levels and localizations in tumor tissue were revealed by immunohistochemistry and evaluated by the semiquantitative method and immunoreactivity score. Majority of glioblastomas had moderate expression levels for both DVL3 (52.4%) and sFRP3 (52.3%). Strong expression levels were observed in 23.1% and 36.0% of samples, respectively. DVL3 was localized in cytoplasm in 97% of glioblastomas, of which 44% coexpressed the protein in the nucleus. sFRP3 subcellular distribution showed that it was localized in the cytoplasm in 94% of cases. Colocalization in the cytoplasm and nucleus was observed in 50% of samples. Wilcox test indicated that the domination of the strong signal is in connection with simultaneous localization of DVL3 protein in the cytoplasm and the nucleus. Patients with strong expression of DVL3 will significantly more often have the protein in the nucleus (P=6.33×10-5). No significant correlation between the two proteins was established, nor were their signal strengths correlated with epidemiological parameters. Our study contributes to better understanding of glioblastoma molecular profile.

Original languageEnglish (US)
Article number9253495
JournalDisease Markers
Volume2017
DOIs
StatePublished - Jan 1 2017

Fingerprint

Glioblastoma
Cytoplasm
Proteins
Tumors
Biomarkers
Nonparametric Statistics
Brain Neoplasms
Brain
Immunohistochemistry
Tissue
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Kafka, A., Tomas, D., Lechpammer, M., Gabud, T., Pažanin, L., & Pećina-Šlaus, N. (2017). Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma. Disease Markers, 2017, [9253495]. https://doi.org/10.1155/2017/9253495

Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma. / Kafka, Anja; Tomas, Davor; Lechpammer, Mirna; Gabud, Tea; Pažanin, Leo; Pećina-Šlaus, Nives.

In: Disease Markers, Vol. 2017, 9253495, 01.01.2017.

Research output: Contribution to journalArticle

Kafka, A, Tomas, D, Lechpammer, M, Gabud, T, Pažanin, L & Pećina-Šlaus, N 2017, 'Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma', Disease Markers, vol. 2017, 9253495. https://doi.org/10.1155/2017/9253495
Kafka, Anja ; Tomas, Davor ; Lechpammer, Mirna ; Gabud, Tea ; Pažanin, Leo ; Pećina-Šlaus, Nives. / Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma. In: Disease Markers. 2017 ; Vol. 2017.
@article{c3e3cc58d8ac45a6842bb68d768d6a3b,
title = "Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma",
abstract = "The expression patterns of critical molecular components of Wnt signaling, sFRP3 and DVL3, were investigated in glioblastoma, the most aggressive form of primary brain tumors, with the aim to offer potential biomarkers. The protein expression levels and localizations in tumor tissue were revealed by immunohistochemistry and evaluated by the semiquantitative method and immunoreactivity score. Majority of glioblastomas had moderate expression levels for both DVL3 (52.4{\%}) and sFRP3 (52.3{\%}). Strong expression levels were observed in 23.1{\%} and 36.0{\%} of samples, respectively. DVL3 was localized in cytoplasm in 97{\%} of glioblastomas, of which 44{\%} coexpressed the protein in the nucleus. sFRP3 subcellular distribution showed that it was localized in the cytoplasm in 94{\%} of cases. Colocalization in the cytoplasm and nucleus was observed in 50{\%} of samples. Wilcox test indicated that the domination of the strong signal is in connection with simultaneous localization of DVL3 protein in the cytoplasm and the nucleus. Patients with strong expression of DVL3 will significantly more often have the protein in the nucleus (P=6.33×10-5). No significant correlation between the two proteins was established, nor were their signal strengths correlated with epidemiological parameters. Our study contributes to better understanding of glioblastoma molecular profile.",
author = "Anja Kafka and Davor Tomas and Mirna Lechpammer and Tea Gabud and Leo Pažanin and Nives Pećina-Šlaus",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/9253495",
language = "English (US)",
volume = "2017",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

AU - Kafka, Anja

AU - Tomas, Davor

AU - Lechpammer, Mirna

AU - Gabud, Tea

AU - Pažanin, Leo

AU - Pećina-Šlaus, Nives

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The expression patterns of critical molecular components of Wnt signaling, sFRP3 and DVL3, were investigated in glioblastoma, the most aggressive form of primary brain tumors, with the aim to offer potential biomarkers. The protein expression levels and localizations in tumor tissue were revealed by immunohistochemistry and evaluated by the semiquantitative method and immunoreactivity score. Majority of glioblastomas had moderate expression levels for both DVL3 (52.4%) and sFRP3 (52.3%). Strong expression levels were observed in 23.1% and 36.0% of samples, respectively. DVL3 was localized in cytoplasm in 97% of glioblastomas, of which 44% coexpressed the protein in the nucleus. sFRP3 subcellular distribution showed that it was localized in the cytoplasm in 94% of cases. Colocalization in the cytoplasm and nucleus was observed in 50% of samples. Wilcox test indicated that the domination of the strong signal is in connection with simultaneous localization of DVL3 protein in the cytoplasm and the nucleus. Patients with strong expression of DVL3 will significantly more often have the protein in the nucleus (P=6.33×10-5). No significant correlation between the two proteins was established, nor were their signal strengths correlated with epidemiological parameters. Our study contributes to better understanding of glioblastoma molecular profile.

AB - The expression patterns of critical molecular components of Wnt signaling, sFRP3 and DVL3, were investigated in glioblastoma, the most aggressive form of primary brain tumors, with the aim to offer potential biomarkers. The protein expression levels and localizations in tumor tissue were revealed by immunohistochemistry and evaluated by the semiquantitative method and immunoreactivity score. Majority of glioblastomas had moderate expression levels for both DVL3 (52.4%) and sFRP3 (52.3%). Strong expression levels were observed in 23.1% and 36.0% of samples, respectively. DVL3 was localized in cytoplasm in 97% of glioblastomas, of which 44% coexpressed the protein in the nucleus. sFRP3 subcellular distribution showed that it was localized in the cytoplasm in 94% of cases. Colocalization in the cytoplasm and nucleus was observed in 50% of samples. Wilcox test indicated that the domination of the strong signal is in connection with simultaneous localization of DVL3 protein in the cytoplasm and the nucleus. Patients with strong expression of DVL3 will significantly more often have the protein in the nucleus (P=6.33×10-5). No significant correlation between the two proteins was established, nor were their signal strengths correlated with epidemiological parameters. Our study contributes to better understanding of glioblastoma molecular profile.

UR - http://www.scopus.com/inward/record.url?scp=85042210069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042210069&partnerID=8YFLogxK

U2 - 10.1155/2017/9253495

DO - 10.1155/2017/9253495

M3 - Article

VL - 2017

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 9253495

ER -